BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 22468703)

  • 41. Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma.
    Adeberg S; Bostel T; Harrabi S; Bernhardt D; Welzel T; Wick W; Debus J; Combs SE
    BMC Cancer; 2015 Jul; 15():558. PubMed ID: 26223282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
    Gao YT; Chen XB; Liu HL
    Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
    Khasraw M; Lee A; McCowatt S; Kerestes Z; Buyse ME; Back M; Kichenadasse G; Ackland S; Wheeler H
    J Neurooncol; 2016 May; 128(1):163-171. PubMed ID: 26935578
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines.
    Combs SE; Bohl J; Elsasser T; Weber KJ; Schulz-Ertner D; Debus J; Weyrather WK
    Int J Radiat Biol; 2009 Feb; 85(2):126-37. PubMed ID: 19280465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
    Achari R; Arunsingh M; Badgami RK; Saha A; Chatterjee S; Shrimali RK; Mallick I; Arun B
    Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):335-343. PubMed ID: 28188088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
    Thon N; Thorsteinsdottir J; Eigenbrod S; Schüller U; Lutz J; Kreth S; Belka C; Tonn JC; Niyazi M; Kreth FW
    J Neurol; 2017 Feb; 264(2):350-358. PubMed ID: 27921166
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.
    Zarnett OJ; Sahgal A; Gosio J; Perry J; Berger MS; Chang S; Das S
    JAMA Neurol; 2015 May; 72(5):589-96. PubMed ID: 25822375
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
    Shenouda G; Souhami L; Petrecca K; Owen S; Panet-Raymond V; Guiot MC; Corredor AG; Abdulkarim B
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):487-494. PubMed ID: 28011051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
    Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
    J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro.
    Koh HK; Seo SY; Kim JH; Kim HJ; Chie EK; Kim SK; Kim IH
    Cancer Res Treat; 2019 Apr; 51(2):696-705. PubMed ID: 30121967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells.
    Kaina B; Beltzig L; Piee-Staffa A; Haas B
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
    Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
    Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
    Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
    Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
    [TBL] [Abstract][Full Text] [Related]  

  • 56. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
    Zhang J; Hummersone M; Matthews CS; Stevens MF; Bradshaw TD
    Oncology; 2015; 88(1):28-48. PubMed ID: 25277441
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
    Xipell E; Aragón T; Martínez-Velez N; Vera B; Idoate MA; Martínez-Irujo JJ; Garzón AG; Gonzalez-Huarriz M; Acanda AM; Jones C; Lang FF; Fueyo J; Gomez-Manzano C; Alonso MM
    Neuro Oncol; 2016 Aug; 18(8):1109-19. PubMed ID: 26951384
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.
    Chakravarti A; Erkkinen MG; Nestler U; Stupp R; Mehta M; Aldape K; Gilbert MR; Black PM; Loeffler JS
    Clin Cancer Res; 2006 Aug; 12(15):4738-46. PubMed ID: 16899625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
    Nie E; Jin X; Wu W; Yu T; Zhou X; Shi Z; Zhang J; Liu N; You Y
    J Neurooncol; 2017 May; 133(1):59-68. PubMed ID: 28425046
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
    Franceschi E; Depenni R; Paccapelo A; Ermani M; Faedi M; Sturiale C; Michiara M; Servadei F; Pavesi G; Urbini B; Pisanello A; Crisi G; Cavallo MA; Dazzi C; Biasini C; Bertolini F; Mucciarini C; Pasini G; Baruzzi A; Brandes AA;
    J Neurooncol; 2016 May; 128(1):157-162. PubMed ID: 26943851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.